Table 1 Clinicopathologic characteristics
Characteristic | PNI negative (n = 76) | PNI positive (n = 58) | P |
|---|---|---|---|
Age (years) | 57.16 ± 10.28 | 55.34 ± 8.24 | 0.273 |
Male | 41 (53.9) | 35 (60.3) | 0.459 |
Location | 0.781 | ||
Hilar | 13 (17.1) | 11 (19.0) | |
Peripheral | 63 (82.9) | 47 (81.0) | |
HBsAg | 0.001 | ||
Negative | 46 (60.5) | 50 (86.2) | |
Positive | 30 (39.5) | 8 (13.8) | |
Tumor size (cm) | 0.945 | ||
≤ 5 | 31 (40.8) | 24 (41.4) | |
> 5 | 45 (59.2) | 34 (58.6) | |
Multiple tumor | 0.548 | ||
No | 56 (73.7) | 40 (69.0) | |
Yes | 20 (26.3) | 18 (31.0) | |
Vascular invasion | 0.148 | ||
No | 50 (65.8) | 31 (53.4) | |
Yes | 26 (34.2) | 27 (46.6) | |
Capsular invasion | 0.521 | ||
No | 39 (51.3) | 33 (56.9) | |
Yes | 37 (48.7) | 25 (43.1) | |
Visceral invasion | 0.441 | ||
No | 63 (82.9) | 45 (77.6) | |
Yes | 13 (17.1) | 13 (22.4) | |
AJCC T stage | 0.486 | ||
1 and 2 | 36 (47.4) | 31 (53.4) | |
3 and 4 | 40 (52.6) | 27 (46.6) | |
AJCC N stage | 0.503 | ||
0 | 52 (68.4) | 34 (58.6) | |
1 | 16 (21.1) | 16 (27.6) | |
x | 8 (10.5) | 8 (13.8) | |
AJCC tumor stage | 0.672 | ||
I | 20 (26.3) | 14 (24.1) | |
II | 9 (11.8) | 10 (17.2) | |
III | 47 (61.8) | 34 (58.6) | |
Tumor differentiation | 0.133 | ||
Well to moderate | 29 (38.2) | 15 (25.9) | |
Poor to undifferentiated | 47 (61.8) | 43 (74.1) | |
Liver cirrhosis | 0.071 | ||
No | 45 (59.2) | 43 (74.1) | |
Yes | 31 (40.8) | 15 (25.9) | |
ALT (U/L) | 0.116 | ||
≤ 40 | 52 (68.4) | 32 (55.2) | |
> 40 | 24 (31.6) | 26 (44.8) | |
AST (U/L) | 0.656 | ||
≤ 40 | 50 (65.8) | 36 (62.1) | |
> 40 | 26 (34.2) | 22 (37.9) | |
PLT (×10^9/L) | 225.55 ± 92.82 | 231.22 ± 91.17 | 0.725 |
CEA (ng/ml) | 0.910 | ||
≤ 5 | 57 (75.0) | 43 (74.1) | |
> 5 | 19 (25.0) | 15 (25.9) | |
CA19–9 (U/ml) | 0.017 | ||
≤ 200 | 51 (67.1) | 27 (46.6) | |
> 200 | 25 (32.9) | 31 (53.4) | |
CA242 (U/ml) | 0.134 | ||
≤ 20 | 44 (57.9) | 26 (44.8) | |
> 20 | 32 (42.1) | 32 (55.2) | |
Child-Pugh score | 0.259 | ||
A | 68 (89.5) | 48 (82.8) | |
B | 8 (10.5) | 10 (17.2) | |
Postoperative chemotherapy | 0.409 | ||
No | 66 (86.8) | 53 (91.4) | |
Yes | 10 (13.2) | 5 (8.6) | |
Post-recurrence anti-tumor therapy | 0.987 | ||
Yes | 51 (67.1) | 5 (67.2) | |
No | 25 (32.9) | 28 (32.8) |